Recent Company News

• 02:25 PM ET Feb 02, 2026
  

  StreetAccount Summary - US equity offerings expected to price for Tuesday, 03-Feb

• 09:29 AM ET Feb 02, 2026
  

  StreetAccount Summary - US Syndicate recap for 02-Feb

• 08:36 AM ET Feb 02, 2026
  

  StreetAccount Summary - US Initial Syndicate recap for 02-Feb

• 03:03 PM ET Jan 30, 2026
  

  StreetAccount Summary - US equity offerings expected to price for week of 02-Feb

• 08:01 AM ET Jan 27, 2026
  

  Belite Bio completes enrollment in DRAGON II clinical trial of tinlarebant for Stargardt disease (STGD1) ($162.47, 0.00)

• 06:56 PM ET Jan 26, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:58 AM ET Jan 26, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:01 AM ET Jan 26, 2026
  

  Belite Bio initiated buy at BofA ($164.58, 0.00)

• 09:46 AM ET Jan 06, 2026
  

  StreetAccount Sector Summary: Healthcare Monthly Recap - December 2025

• 06:04 AM ET Jan 06, 2026
  

  Belite Bio initiated overweight at Morgan Stanley ($159.42, 0.00)